Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC - Archive ouverte HAL Access content directly
Preprints, Working Papers, ... Year :

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

Rémi Gence
Raghda Asslan
  • Function : Author
Sandra Pagano
  • Function : Author
Claudine Tardy
Jacques Colinge
Jean-Philippe Villemin
  • Function : Author
Antonio Maraver
Irene Ferrer
  • Function : Author
Luis Paz-Ares
Isabelle Lajoie-Mazenc
Estelle Clermont
  • Function : Author
Anne Casanova
  • Function : Author
Anne Pradines
Julien Mazières

Abstract

Drug-tolerant "dormant" cells (DTC) have emerged as one of the major non-genetic mechanisms driving resistance to targeted therapy in lung cancer, although the sequence of events leading to entry and exit from dormancy remain poorly described. Here, we performed real-time monitoring of the cell cycle dynamics during the adaptive response to Epidermal Growth Factor Receptor tyrosine kinase inhibitors (EGFR-TKi) in a panel of EGFR-mutated lung cancer cell lines. We identified a rare population of S/G2 cycling cells (referred to as early escapers) that emerged in the first
Fichier principal
Vignette du fichier
2022.04.01.486707v1.full.pdf (2.48 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03843955 , version 1 (08-11-2022)

Identifiers

Cite

Sarah Figarol, Célia Delahaye, Rémi Gence, Raghda Asslan, Sandra Pagano, et al.. Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC. 2022. ⟨hal-03843955⟩
4 View
2 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More